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Background: Hospital admission for neutropenic fever in patients with AML is a standard practice.
However, discharge practices vary once patients become afebrile, with many patients hospitalized until
rise in the absolute neutrophil count (ANC) to 4500 (ANC recovery). Data to support this practice are
sparse. We hypothesized that patients admitted for neutropenic fever, particularly if in complete
remission (CR) or about to enter CR following the chemotherapy course associated with neutropenic
fever, might be safely discharged earlier (ED). Beneﬁts of ED are less exposure to hospital pathogens,
reduced cost, increased availability of beds for patients more in need of urgent care, and potentially,
enhanced psychological well-being.
Methods: We identiﬁed patients age 18–70 with newly diagnosed AML who were admitted to the
University of Washington Medical Center with neutropenic fever between January 2008 and May 2010.
We compared subsequent (within 30 days of discharge) deaths, intensive care unit (ICU) admissions,
and readmissions for neutropenic fever according to discharge ANC, regarded as a numerical variable
using the Mann–Whitney U test and as o500 vs 4500 using the Fisher Exact test. We used the Mann–
Whitney U or Spearman correlation to analyze the relation between ANC at discharge and other
covariates that might have affected outcome: age, ECOG performance status at admission for
neutropenic fever, days inpatient, remission status, and type of infection (pneumonia, gram negative
bacteremia, others).
Results: We evaluated 49 patients discharged after admission for neutropenic fever, 26 of whom were
discharged with an ANC o500. Thirty ﬁve of the patients were in CR or entered CR following the
chemotherapy course associated with their neutropenic fever admission. Patients who were discharged
with lower ANC were more likely to be readmitted with neutropenic fever (Mann–Whitney U p¼0.03),
although this was not true using ANC categorized as o vs 4500 (Fisher Exact p¼0.24, 95% conﬁdence
interval 0.47, 0.11). There was no relation between ANC at discharge and subsequent admission to an
ICU (Mann–Whitney U p¼0.50, Fisher Exact p¼0.64, 95% conﬁdence interval 0.2, 0.34 using the 500
ANC cut off). One patient died: a 55 year old discharged with ANC 0 after successful treatment of
neutropenic fever died 19 days after hospital readmission with fever of unknown origin. Stenotropho-
monas maltophilia pneumonia and sepsis were discovered 14 days after readmission. Assuming a beta
distribution and rates of death of 1/26 for discharge with ANCo500 and 0/23 for discharge with
ANC4500, the probability that a discharge ANC with o500 is associated with a higher death rate is
0.019. The number of events was too small for a multivariate analysis. However, patients with better
performance status (oECOG 2) or who spent a shorter time in hospital after admission for neutropenic
fever were more likely to be discharged with lower ANC (Fisher exact p¼0.09 and Spearman p¼0.02
respectively), while the likelihood of discharge with ANCo500 was unrelated to age, remission status,
or type of infection. Thus we examined the relation between ANC and readmission for neutropenic
fever separately in patients with better or worse performance status and in patients who spent more or
less than the median time (8 days) in hospital after admission for neutropenic fever. This analysis
indicated that patients discharged with lower ANC were more likely to be readmitted only if they hadr Research Center, Clinical Research Division, Seattle, USA. Tel.: þ1 206 354 1731.
how).
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Conclusions: Our results suggest that an ANC of 500 is an excessively high cut off for discharge
following hospitalization for neutropenic fever. The rate of rise of the ANC, as well as its absolute value,
may also play a role.
& 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Patients with acute myeloid leukemia (AML) are at increased
risk for developing serious infections after receiving cytotoxic
chemotherapy4. Admission to hospital and administration of
broad spectrum antibiotics is thus standard should patients
develop fever while neutropenic (NF)5,7. However, discharge
practices vary once such patients become afebrile, with many
patients remaining hospitalized until rise in their absolute neu-
trophil count (ANC) to 4500/mL (ANC recovery). There are
several reasons to question this practice. First, today’s antibiotics
are probably more effective than those available when the
practice was initiated. Second, Bodey et al. noted that at a given
neutrophil count o1000 infections were less common in patients
in remission than in those not2. Third, keeping patients in hospital
until ANC recovery increases their exposure to hospital-acquired
infections and may decrease psychological well-being. Finally,
this policy increases costs and/or decreases the availability of
beds for patients more in need of urgent care1,3,8. These con-
siderations motivated us to retrospectively compare rates of
re-admission, admission to ICU, and death (from the event
prompting re-admission) according to discharge ANC in patients
discharged from hospital after apparent successful treatment of
NF. Here we report our results.Table 1
Patient characteristics.
Discharge ANCo500/mL Discharge ANC4500/mL
Patients N¼26 N¼23
Median ANC @ discharge 0.13 (range 0–0.45) 1.47 (range 0.61–13.57)
Median age (yrs) 55 (range 20–67) 51 (range 18–70)
ECOG performance status @ admission for NF
0–2 22 (84.6%) 16 (69.6%)
3–4 4 (15.4%) 7 (30.4%)
Median # days inpatient prior to initial discharge
7 (range 3–60) 10 (range 4–57)
In/Entering CR
YES 16 (61.5%) 19 (82.6%)
NO 10 (38.5%) 4 (17.4%)
Infections prompting ﬁrst NF admission
Pneumonia 3 (11.5%) 3 (13%)
GNB 3 (11.5%) 2 (8.7%)
Other 20 (77%) 18 (78.3%)
Re-admission 9 (35%) 4 (17%) (p¼0.24)
Re-admission to ICU 2 (8%) 3 (13%) (p¼0.64)
Death 1 (4%) 02. Materials and methods
After obtaining IRB approval we reviewed the medical records
(accessed electronically) of 144 patients given chemotherapy for
newly-diagnosed AML at the University of Washington/Seattle
Cancer Care Alliance (UW/SCCA) between January 2008 and May
2010. Essentially all 144 received ‘‘3þ7’’ or ‘‘more intense’’
regimens, particularly those containing ara-C at a daily dose
Z1 g/m2. Forty-nine of the 144 were admitted because of NF (a
single oral temperature Z38.3 1C or a temperature Z38 1C for
Z1 h unrelated to transfusion and accompanied by an ANC of
o500/mL, or 4500/mL with a predicted decline to o500/mL, in
accordance with 2010 Infectious Disease Society of America
criteria).6 For each of the 49, this admission was the ﬁrst for NF.
Patients were included regardless of whether they were receiving
induction or post-remission therapy and regardless of whether or
not they were in complete remission (CR). Thirty-ﬁve of the 49
(71%) were thought to be in CR or were shown to be in CR at the
next marrow exam.
We classiﬁed ANC at discharge after seemingly successful
treatment of NF in two ways. First we used the actual ANC on
day of discharge and employed the Mann–Whitney test to
compare distribution of discharge ANC count in (a) patients
who were or were not re-admitted to hospital for NF within 30
days of discharge, (b) patients who were or were not admitted to
ICU within 30 days of discharge, and (c) patients who died vs
those who survived these 30 day after discharge. Second we
categorized the discharge ANC as o vs 4500 (a commonly used
criterion for discharge) and used the Fisher exact test to compare
the rates of the above outcomes according to whether the ANC
was below or above this level. In general patients were dischargedon levoﬂoxacin or ciproﬂoxacin and ﬂuconazole. Exceptions were
patients in whom an organism had been isolated from blood;
such patients were typically discharged on antibiotics appropriate
for that organism, e.g. vancomycin for coagulase negative staph.
We also examined the relation between discharge ANC and the
following: age, performance status (PS) [0–2 vs 3–4] as evaluated
at initial admission for NF, CR status (yes/no), and cause of the
NF—pneumonia, gram negative bacteremia (GNB), other (includ-
ing fever of unknown origin) prompting the initial admission for
NF. These relations were analyzed using Spearman correlation,
Mann–Whitney, or Fisher exact depending on whether covariates
were numerical (e.g. age) or binary (e.g. ANC o vs 4500,
performance status 0–2 vs 3–4).3. Results
Table 1 shows some characteristics of the 49 patients. Thirteen
(27%) patients were re-admitted, all for NF. The rate of read-
mission increased as the discharge ANC became lower (p¼0.03).
However the ANC 500 cut-off point did not clearly distinguish
patients who were and were not re-admitted (Table 1). Nor was
there a relation between the ANC at discharge (actual value or
o500 vs 4500) and subsequent need for ICU admission. One
patient died within 30 days of discharge. She was a 55 year old
who was discharged afebrile with ANC of 0 after a hospital stay of
21 days; the cause of this fever was not determined. She was re-
admitted with fever the next day while her ANC remained 0. She
was intermittently febrile and 14 days after re-admission blood
cultures grew Stenotrophomonas maltophilia leading to her death,
at which time her ANC remained 0. This history suggests that the
infection that led to her death was acquired in the hospital.
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We were interested in knowing whether patients who were
discharged before ANC recovery did well because they were
younger, had better PS, or more likely to be in CR than patients
who were not discharged before ANC recovery. However while
patients with better PS (but not age) were more likely to be
discharged than other patients, better PS was not associated with
fewer re-admissions. Likewise patients in CR were not less likely
to be re-admitted. Thus 9 of the 35 patients (26%) who were in CR
or shown to be in CR at their next marrow after initial NF were
readmitted for a subsequent NF within 30 days of discharge vs
4 of the 14 patients who were not in CR. The contrast between
this ﬁnding and Bodey et al.’s2 likely reﬂects the development of
better antibiotics and correspondingly less need for reliance on
normally functioning neutrophils (as in patients in CR).
A point made by Bodey et al. that still seems true however is
that the trend in neutrophil count is a better predictor than a
cutoff value such as 500. Speciﬁcally, only 3 of the 22 patients
(14%) whose neutrophil count increased by 500 or more between
initial admission for NF and discharge were subsequently re-
admitted vs 10 of 27 patients (37%) with less of an increase
(p¼0.10). If we used 50 rather than 500 as the criterion of a rise,
readmission rates were 7/37 (19%) for those with such an increase
vs 6/12 (50%) for those without (p¼0.06).
Our results call into question the practice of keeping patients
admitted for NF in the hospital after successful treatment of the
NF. They also suggest the ANC 500 cut-off point is of limited use,
although the trend of the ANC should be taken into consideration.Funding
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